MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2- advanced breast cancer (ABC)
Z. Jiang(Chinese PLA General Hospital), Xiaolin Hu(Fudan University Shanghai Cancer Center), Q. Zhang(Harbin Medical University), Tao Sun(Liaoning Cancer Hospital & Institute), Y. Yin(Jiangsu Province Hospital), H. Li(Peking University), Ricardo Costa(Instituto do Câncer do Estado de São Paulo), M. Yan(Zhengzhou University), Christina Oppermann(Hospital Mãe de Deus), Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Yuan Liu(First Hospital of China Medical University), Y. Zhang(Dalian Medical University), Yufeng Cheng, Quchang Ouyang(Hunan Cancer Hospital), X. Chen(Fuzhou General Hospital of Nanjing Military Command), Naishun Liao(Guangdong General Hospital), Xinhong Wu(Hubei Cancer Hospital), X. Wang(Zhejiang Cancer Hospital), Rong Han(Lilly (China)), Yongchang Lu(Eli Lilly (United States))
Cited by 15
Abstract
Related Papers
No related papers found
Powered by citation graph analysis